Docosahexaenoic acid in ARSACS: observations in two patients.

Ivana RiccaAlessandra TessaRosanna TrovatoGiacomo Maria BacciFilippo Maria Santorelli

Published in: BMC neurology (2020)

DHA was safe over a long period and well-tolerated by the two patients; both showed a stabilization of clinical symptoms, rather than the expected deterioration, warranting additional investigations in patients with mutations in SACS.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
depressive symptoms